» Articles » PMID: 37462906

Process Robustness in Lipid Nanoparticle Production: A Comparison of Microfluidic and Turbulent Jet Mixing

Abstract

The recent clinical and commercial success of lipid nanoparticles (LNPs) for nucleic acid delivery has incentivized the development of new technologies to manufacture LNPs. As new technologies emerge, researchers must determine which technologies to assess and how to perform comparative evaluations. In this article, we use a quality-by-design approach to systematically investigate how the mixer technology used to form LNPs influences LNPstructure. Specifically, a coaxial turbulent jet mixer and a staggered herringbone microfluidic mixer were systematically compared via matched formulation and process conditions. A full-factorial design-of-experiments study with three factors and three levels was executed for each mixer to compare process robustness in the production of antisense oligonucleotide (ASO) LNPs. ASO-LNPs generated with the coaxial turbulent jet mixer were consistently smaller, had a narrower particle size distribution, and had a higher ASO encapsulation as compared to the microfluidic mixer, but had a greater variation in internal structure with less ordered cores. A subset of the study was replicated for mRNA-LNPs with comparable trends in particle size and encapsulation, but more frequent bleb features for LNPs produced by the coaxial turbulent jet mixer. The study design used here provides a road map for how researchers may compare different mixer technologies (or process changes more broadly) and how such studies can inform process robustness and manufacturing control strategies.

Citing Articles

Continuous Production of Docetaxel-Loaded Nanostructured Lipid Carriers Using a Coaxial Turbulent Jet Mixer with Heating System.

Lim H, Choi W, Lim J Molecules. 2025; 30(2).

PMID: 39860147 PMC: 11767693. DOI: 10.3390/molecules30020279.


Endosomal escape mechanisms of extracellular vesicle-based drug carriers: lessons for lipid nanoparticle design.

Hagedorn L, Jurgens D, Merkel O, Winkeljann B Extracell Vesicles Circ Nucl Acids. 2024; 5(3):344-357.

PMID: 39697635 PMC: 11648457. DOI: 10.20517/evcna.2024.19.


Fabrication of mRNA encapsulated lipid nanoparticles using state of the art SMART-MaGIC technology and transfection in vitro.

Heshmati N, Chakka L, Zhang Y, Maniruzzaman M Sci Rep. 2024; 14(1):22714.

PMID: 39349578 PMC: 11442764. DOI: 10.1038/s41598-024-73804-y.


Toward the scale-up production of polymeric nanotherapeutics for cancer clinical trials.

Mahmud M, Pandey N, Winkles J, Woodworth G, Kim A Nano Today. 2024; 56.

PMID: 38854931 PMC: 11155436. DOI: 10.1016/j.nantod.2024.102314.


Strategies for Improved pDNA Loading and Protection Using Cationic and Neutral LNPs with Industrial Scalability Potential Using Microfluidic Technology.

Ottonelli I, Adani E, Bighinati A, Cuoghi S, Tosi G, Vandelli M Int J Nanomedicine. 2024; 19:4235-4251.

PMID: 38766661 PMC: 11102183. DOI: 10.2147/IJN.S457302.


References
1.
Li S, Hu Y, Li A, Lin J, Hsieh K, Schneiderman Z . Payload distribution and capacity of mRNA lipid nanoparticles. Nat Commun. 2022; 13(1):5561. PMC: 9508184. DOI: 10.1038/s41467-022-33157-4. View

2.
Kloczewiak M, Banks J, Jin L, Brader M . A Biopharmaceutical Perspective on Higher-Order Structure and Thermal Stability of mRNA Vaccines. Mol Pharm. 2022; 19(7):2022-2031. PMC: 9257798. DOI: 10.1021/acs.molpharmaceut.2c00092. View

3.
Tahtinen S, Tong A, Himmels P, Oh J, Paler-Martinez A, Kim L . IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022; 23(4):532-542. DOI: 10.1038/s41590-022-01160-y. View

4.
Hou X, Zaks T, Langer R, Dong Y . Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6(12):1078-1094. PMC: 8353930. DOI: 10.1038/s41578-021-00358-0. View

5.
Jayaraman M, Ansell S, Mui B, Tam Y, Chen J, Du X . Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012; 51(34):8529-33. PMC: 3470698. DOI: 10.1002/anie.201203263. View